Rezolute/$RZLT
1D1W1MYTD1Y5YMAX
Capital at risk
About Rezolute
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
- Ticker
- $RZLT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 68
- Headquarters
- Redwood City, United States
- Website
- www.rezolutebio.com
Rezolute Metrics
BasicAdvanced
$460M
-
-$0.80
0.67
-
Price and volume
Market cap
$460M
Beta
0.67
52-week high
$11.46
52-week low
$1.07
Average daily volume
1.2M
Financial strength
Current ratio
15.842
Quick ratio
15.611
Long term debt to equity
0.375
Total debt to equity
0.951
Profitability
EBITDA (TTM)
-85.823
Management effectiveness
Return on assets (TTM)
-48.74%
Return on equity (TTM)
-81.73%
Valuation
Price to book
3.93
Price to tangible book (TTM)
3.93
Price to free cash flow (TTM)
-6.069
Free cash flow yield (TTM)
-16.48%
Free cash flow per share (TTM)
-0.725
Growth
Earnings per share change (TTM)
-27.82%
3-year earnings per share growth (CAGR)
-10.90%
10-year earnings per share growth (CAGR)
-30.15%
What the Analysts think about Rezolute
Analyst ratings (Buy, Hold, Sell) for Rezolute stock.
Analyst projections of the future price of Rezolute stock.
Bulls say / Bears say
Rezolute’s Phase 3 upLIFT interim analysis showed six of the first eight tumor hyperinsulinism patients met the primary endpoint, fully discontinued IV glucose support, and reported no drug-related safety events, strengthening confidence in ersodetug’s efficacy and tolerability (Zacks)
Following a Type B meeting on March 17, 2026, the FDA acknowledged behavioral confounders in the congenital HI sunRIZE study and encouraged Rezolute to submit comprehensive analyses for independent review, indicating regulatory receptivity that may expedite congenital HI approval pathways (SEC 8-K)
As of March 31, 2026, Rezolute held $120.3 million in cash, cash equivalents and marketable securities, providing sufficient runway into the second half of 2027 to fully fund its Phase 3 programs without immediate financing needs (SEC 8-K)
The Phase 3 sunRIZE study in congenital HI did not achieve its primary endpoint, raising questions about ersodetug’s statistical efficacy in CHI and potential requirements for additional trials before approval (SEC 8-K)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Rezolute Financial Performance
Revenues and expenses
Rezolute Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Rezolute
Fund name | Fund size | $RZLT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.